MedTrace Logo

Observation Study to Evaluate the Efficacy and Safety of Ifosfamide/Mesna in Patients With Metastatic Castration-resistant Prostate Cancer

NCT06236789 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2024-02-01

No results posted yet for this study

Summary

Prostate cancer is the 2nd most common cancer in men worldwide. Based on the results of several recent clinical trials, systemic treatments including hormone inhibitors, docetaxel, cabazitaxel, and PARP inhibitors are being used as standard treatment for patients with metastatic castration-resistant prostate cancer. However, there is insufficient research on salvage therapy for patients with metastatic castration-resistant prostate cancer who have failed standard treatment. In this study, the investigators will evaluate the effectiveness and safety of ifosfamide in castration-resistant prostate cancer by analyzing the treatment outcomes of patients who received ifosfamide/mesna treatment as salvage therapy.

Conditions

  • Prostatic Neoplasm

Interventions

DRUG

Ifosfamide/mesna

Ifosfamide 2,500 mg/m2/day for 3 days every 3 weeks with mesna until disease progression

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Principal Investigators

  • Sang Joon Shin · Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine

Eligibility

Min Age
19 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2026-11-30
Completion
2026-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06236789 on ClinicalTrials.gov